Some of the problems with unproductive relaxing treatments and insufficient repair aptitude in the central nervous system are most troubling problems for few neurological diseases. Providentially, the development of clinically relevant populations of stem cells has provided an opportunity to overcome the failure of endogenous repair systems and substitute new cells into the injured brain. However, there are still several existing difficulties in interpreting into clinical application. In this review, we mainly focus on the stem cell based therapies for Parkinson's disease and discuss the possible advantages and drawbacks. We hope this review may provide suggestions for viable policies to overcome the current technical and biological issues relatedto the application of stem cells in Parkinson's disease (Fu et al., 2015) .
INTRODUCTION
The Stem cells have the potential to develop into many different types of cells in the body. It mostly serves as a repair system for the body. This type of cells is of two type embryonic cells and adult cells.On a division, the stem cells have a potential while repairing it remains same or develop into another type of cell with more sophisticated functions it mostly develops as a muscle, brain or RBC cells. The stem cells consist of many different types of cells it many modifies the embryonic and adult cell used to differentiate stem cells by the developmental stage of the animal from where this cellscome. The adult stem cells more correctly termed as "somatic" stem cells meaning from the body mostly found in the fetus, umbilical cord blood, placenta, and infants. In the 3-to 5-day-old embryo, called a blastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lung, skin, sperm, eggs and other tissues. In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease. In laboratory scientist and researchers are continuously working on various aspects of stem cell how they are different from other cells, there essential properties and what makes them different from specialized cell types. Many new researchers are also using the stem cell for the screening of new Drugs moiety apart from this it also helpful for the development of model systems to study normal growth and identification of causes of birth defects (Canet et 
ON THE BASIS OF POTENCY
The stem cell classification on the basis of potency:
Totipotent: These types of cells are having the ability to differentiate into all possible cell types. Examples are the zygote formed at egg fertilization and the first few cells that result from the division of the zygote.
Pluripotent:
The ability to differentiate into almost all cell types. Examples include embryonic stem cells and cells that are derived from the mesoderm, endoderm, and ectoderm germ layers that are formed in the beginning stages of embryonic stem cell differentiation.
Multipotent:
The ability to differentiate into a closely related family of cells. Examples include hematopoietic (adult) stem cells that can become red and white blood cells or platelets.
Oligopotent:
The ability to differentiate into a few cells. Examples include (adult) lymphoid or myeloid stem cells.
Omnipotent:
The ability to only produce cells of their own type, but have the property of self-renewal required to be labeled a stem cell. Examples include (adult) muscle stem cells. 
ON THE BASIS OF SOURCES

NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE
STEM CELL THERAPY
The stem cell is the techniques most useful for cure of injury or treats the disease. This type of cell is having the ability to self-renew which offers significant potential for generation of tissue that can potentially replace diseased and damaged area in the body with minimum risk of rejection and side effects (Rusu, E. et al., 2016) The medical researcher anticipate that adult and embryonic stem cell will soon be able to treat cancer, diabetes, parkinsonism, Huntington's disease, etc.  The cells should possess the molecular, morphological and electrophysiological properties of dopaminergic neurons in substantia nigra;  The therapy should enable 100,000 or more DA neurons to survive long-term in human putamen;  The grafted cells should re-establish a dense terminal network throughout the striatum to functionally integrate into host neural circuitries. Here we review the progress of stem cell therapies and discuss the major problems encountered in Parkinson's disease.
Graft (Implantation):
The content of graft is the serious issue when performing the transplantation. It is presently unknown whether symptomatic relief would be best achieved by implanting of DA neurons or a graft containing a portion of glial cells. ES cell derived DA neurons ES cells are one important source that has been used to differentiate into DA neurons in the laboratory. DA neurons derived from rodents and humans have been shown to survive and function after transplantation into the striatum of PD rats (Kim et al. 2002) . Furthermore, the uptake of [18F]-DOPA also increased 14 weeks after transplantation, suggesting exogenous ES cellderived DA neurons could offer the functional recovery of DA neurons. Until now, ES cells are still the most promising source to differentiate into DA neurons (Kim et al. 2002) ; however, the efficiency to differentiate into DA neurons and the existence rate of these neurons after transplantation is still low. For example, prior reports showed less than 300 tyrosine hydroxylase (TH)-positive neurons survived after transplanting 100,000-400,000 ES cells into the striatum. Therefore a critical issue that must be resolved to enhance recovery after transplantation in PD is an improvement of the differentiation and survival rate (Bergman and Deuschl, 2002) iPSC-derived DA neurons: (Nguyen, Parkinson's disease model. However, the survival rate of TH positive neurons after a replacement was less than 4.3 %. The auxiliary of NSCs from SVZ boosted the recovery of Parkinson's disease symptoms, but the survival rate of these cells was still low. Therefore, the most important matter that must be overcome in order to achieve NSC relocation is to increase the cell number and existence rate of transplanted cells. (Nguyen, H.N., et al., 2011)
IMMUNE RESPONSE
Although the brain is considered as an immuneprivileged site, the host immune system still responds to the grafts. The interaction between implantation and the endogenous immune system affects the survival of grafted cells. In several clinical trials, transplantation without adequate immunesuppression may have led to poor outcomes, while transplantation with an immune-suppressant, such as cyclosporine, azathioprine, and prednisolone, produced better effects (Lindvall et al. 1987 ). Unfortunately, patient symptoms worsened after withdrawal of immune-suppression, and postmortem showed grafts were surrounded by activated microglia and immune reactivity. These results imply that immune reactions exert a negative effect during transplantation, and it would be necessary to use an immunosuppressant in combination with grafting; however, further studies are still needed to determine the optimal immunosuppressant and the period of treatment.
(de la Fuente-Fernandez , R et al., 1998)
MAJOR DISPUTES AFTER GRAFTS:
Depending on the reports of several cell-based studies in both animals and humans, there are two major apprehensions related to grafts. Graft Induced Dyskinesia (GID) (Fu, M.-H et al., 2015) The occurrence of dyskinesia after transplantation was first reported by Defer et al. (1996) , but did not obtain much courtesy till Freed's trial in 2001. They described the development of "graft persuaded dyskinesia (GID)" in 15 % of transplanted patients 1 year after transplantation. This surprising symptom reached 56 % in Olanow's study. It is speculated that the number of grafted cells used in the surgerycontrolled clinical trials was less than those of other more successful studies (Lindvall et al. 1987 ). Furthermore, immune-suppression may be also an important aspect since dyskinesia did not develop till immunosuppression withdrawal in several reports. The other possible dispute is that other varied grafts were originated in ventral putamen, containing serotonergic neurons. These grafts led to islands of reinnervation and abnormal production of DA. Hence, transplanting a sufficient number of cells having a pure population of DA neurons in basal ganglion with immunosuppression is suggested to avoid the progress of GID.
Grafts affected by PD process: Indications that PD pathology may propagate from host to grafts is emerging. The presence of LBs and Lewy neurites in grafted DA neurons were generally observed 11-16 years after human fetal mesencephalic transplantation however,α-syncline staining is generally not detectable in adults younger than 20-year. These observations imply that PD pathology can be transferred from host to graft. The exact reasons for this negative outcome remain unresolved. A recent report showed that fetal cell transplantation in two PD patients remains highly functional even 15-18 years after surgery. Therefore, although the spread of PD pathology may occur after transplantation, the period of beneficial effects from transplantation is still longer than that of current medications, suggesting stem cells still could be a potential clinical therapy (Rana, 2011) .
MECHANISMS OF STEM CELL THERAPY IN PARKINSON'S DISEASE
The mechanism is classified in two ways it includes: Direct Repair Pathway. 2. Indirect Repair Pathway 1. Direct repair pathway: It includes supplementing endogenous neurogenesis, DA neuron differentiation, DA release, striatum reinnervation and neural trails integration.
Indirect repair system through trophic factors:
Stem cells express various neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), cerebral dopamine neurotrophic factor (CDNF), nerve growth factor (NGF), or glial-derived neurotrophic factor (GDNF), and facilitate DA neuronal differentiation and maintenance. These passerby effects are mainly likely to result from Vol. 6, Issue 6 | www.pharmatutorjournal.com We need to detect the outcome measures that are meaningful not only to investigators and clinicians but also to patients and for that we will work in partnership with end users in order to safeguard our key outcomes which are related to patient perspective. As a mean, we will early on establish a "user board". An ultimate challenge is also to explicitly identify/develop tools that imitate real-life challenges (e.g. outdoor mobility) in standardized settings to certify that potential treatment effects translate into "real-world" settings. Pilot tests are then needed well advance of a clinical trial in order to determine the acceptability, probability, and reliability of such assessments. Toobin-depth investigate the patient viewpoint, qualitative methods (e.g. interviews) will be used as a complement to quantitative methods that include both unbiased measures and patient-reported outcomes measures. Taken together, our measurements will hit the difficulty of health condition such as PD by covering both functions, activities of importance in daily life and participation, i.e. "involvement in life situations". (Lindvall and Kokaia 2006; Lindvall et al. 1987) .
CONCLUSION
From the above theories, it has been concluded that there is still no perfect treatment for Parkinson's disease has been developing yet. However, the outcomes from the clinical trials have not been proven consistent or convincing. This may be due to a combination of factors, such as patient selection, amount and mode of tissue engraftment and the level of immune-suppression. Moreover, another side effect to be considered is GID. Fortunately, grafted tissues were unaffected by PD progression within 10 years after transplantation, so the treatment of PD with stem cell grafts is still a favorable direction. The major advantage of this strategy is the restorative and trophic abilities of the grafted cells which reach far away from drugs prescribed in a recent practice. Another thing is the regeneration of dopaminergic neurons and the maintenance of dopamine homeostasis which are important for successfully treating this disease as the patients with PD are greatly affected by the loss of dopaminergic neuron. However, the major problem to developing therapeutic strategies for neurodegenerative diseases is the brain complexity. Due to the reason that the transplanted stem cells can redevelop neurons and glia in an optimal microenvironment and produce neuroprotective molecules, the stem cell therapy has great potential to treat PD as well as other neurodegenerative diseases.
